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FeNO measurement in respiratory diseases 831anti-inflammatory therapy, and the ability to predict risk of future exacerbations or decline in
lung function. Despite these data, concerns regarding the applicability and utility of FeNO in
clinical practice still remain. This article reviews the current evidence, both supportive and
critical of FeNO measurement, in the diagnosis and management of asthma and other inflam-
matory airway diseases. It additionally provides suggestions regarding the practical application
of FeNO measurement: how it could be integrated into routine clinical practice, how its utility
could be assessed and its true value to both clinicians and patients could be established.
Although some unanswered questions remain, current evidence suggests that FeNO is poten-
tially a valuable tool for improving the personalised management of inflammatory airway dis-
eases.
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The majority of patients presenting to primary care physi-
cians with non-specific respiratory symptoms such as
wheeze, cough and breathlessness are treated with inhaled
corticosteroids based on the presumptive diagnosis of
asthma [1]. On detailed assessment, however, many pa-
tients lack objective evidence of asthma or inflammatory
airway disease [1,2].
The identification of airway obstruction and abnormal
airways physiology is the objective of diagnostic tests such
as spirometry, reversibility testing, peak flow monitoring,
and bronchoprovocation tests, commonly used in the
investigation of airway disease [3,4]. However, diagnosis
and management of patients with airway diseases based on
these physiological parameters alone without assessing
underlying inflammation may be inadequate in targeting
anti-inflammatory treatment to those who lack confirma-
tory evidence. This is important as ineffective treatment is
costly and may also be associated with adverse effects,
while delaying appropriate treatment. Hence, exploringmore adequate diagnostic and management strategies is
required. In addition to current practice would be the
assessment of airway inflammation and corticosteroid
responsiveness on an individual basis for a personalized
diagnostic and treatment approach. One such approach
involves measuring the fraction of exhaled nitric oxide
(FeNO), which can be performed easily and in close to real
time by utilising chemiluminescence, electrochemical
detection or laser spectroscopy devices [5], and which has
the potential to identify patients with corticosteroid-
responsive, T-helper cell 2 (Th2)-mediated airway inflam-
mation [6]. In conjunction with symptom scores and lung
function tests, FeNO measurement could provide a more
useful and effective approach for the identification of
asthma and other corticosteroid-responsive inflammatory
airway conditions.
Nitric oxide synthase (NOS) enzymes, which catalyse the
conversion of L-arginine to L-citrulline to generate NO exist in
three distinct isoforms: endothelial (eNOS), inducible
(iNOS), and neuronal (nNOS) [7]. Recent evidence shows that
in atopic asthmatics, the upregulation of iNOS in the
832 L. Bjermer et al.respiratory epithelium via STAT-6 and pro-inflammatory Th2-
cytokines interleukin (IL)-4 and IL-13 [6], produces enhanced
NO concentrations in exhaled air [8,9]. Exhaled NO, can thus
be regarded as a direct biomarker of Th2-mediated mecha-
nisms within the bronchial mucosa, and can provide a direct
indication of ongoing Th2-driven inflammation. Further
research shows that in patients with Th2-driven airway
inflammation, FeNO measurement provides information on
potential responsiveness to corticosteroid treatment. FeNO
may consequently provide the ability to (i) identify in-
dividuals with inflammatory airway diseases who will benefit
from existing and future anti-inflammatory treatments,
particularly inhaled corticosteroid (ICS) treatment
[4,10e12], and (ii) to monitor and manage the treatment of
patients with inflammatory airway diseases [13].
We believe that personalised strategies, specifically the
application of inflammometry, should be rigorously
assessed for widespread use in clinical practice, including
analysis of cost-effectiveness. This would allow formal
testing of the practical utility of such an integral and per-
sonalised approach in daily routine care.Factors influencing FeNO measurement and
interpretation
Individual factors
Certain considerations should be applied when interpreting
FeNO values as they are influenced by various factors. A
consistent finding in children is that FeNO levels increase
with age, most likely due to increases in airway mucosal
surface area. Data in adults are inconsistent, with variations
in the age ranges of normal subjects included in these
studies. Olin et al. showed that individuals aged >64 years
had40%higher FeNO levels than those aged 35e44 years [14].
This finding was corroborated by Gelb et al., who recently
showed that the effect of age on FeNO is greater in in-
dividuals >60 years [15]. Another study, also conducted in
healthy, non-smoking adults with normal spirometry values
showed no correlation between age and FeNO, but few older
subjects were included in this study. Instead, a significant
gender difference was observed; at expiratory flows of
50mL/s,meanFeNO levelswere 11.7 (range2.6e28.8ppb) in
men and 9.9 (range 1.6e21.5 ppb) in women (pZ 0.01) [16].
Most studies show a relationship between height and FeNO
levels, both in children and adults [14,17]. Recent studies
have indicated that a more accurate and generalisable
interpretation of FeNO could be derived by taking individualTable 1 Clinically important confounding factors for FeNO meas
manage these in clinical practice.
Factor Effect size
Cigarette smoking Reduction of 30e60%, depende
daily cigarette consumption
Rhinovirus infections Increase of 50e150%
Intake of nitrate-containing
food
Increase of up to 40e60%, with
1e2 h after intakefactors into consideration and assessing values based on
percent predicted of reference values, or z-scores [18,19].
However, in a recent study including 13,275 participants
aged 6e80 years (normal population), prediction equations
based on multiple linear regression models justified only
10.3e15.7% of the variation in FeNO levels [20]. Thus, the
prediction equation models need to be improved.
External factors
Cigarette smoking has consistently been shown to reduce
FeNO levels, and the magnitude of the reduction seems to
depend on the daily cigarette consumption [21,22]. How-
ever, FeNO is still raised in smokers with asthma, compared
to smokers without asthma, and it has been shown that
FeNO can differentiate asthma from non-asthma with
asthma-like symptoms equally well in smokers as in never-
smokers [23]. In contrast, FeNO increases following con-
sumption of nitrate rich food, for example green-leaved
vegetables such as lettuce and spinach [6,24]. ATS/ERS
guidelines recommend performing FeNO measurements
before spirometric manoeuvres [25]. However, while some
studies show a marginal reduction in FeNO levels in children
[26], others show no effect in adults [27,28]. In addition to
individual determinants, other factors including allergen
exposure, rhinovirus infections, physical exercise, and air
pollution influence FeNO [6]. IgE sensitisation and subse-
quent allergen exposure has been reported to increase
FeNO levels in asthmatic individuals [29e33]. Rhinovirus
infections induce increases in FeNO levels as a result of
upregulated iNOS expression in airway epithelium [34].
Discrepant effects of exercise on FeNO have been reported;
some studies show up to a 10% decrease in FeNO following
exercise in healthy and asthmatic subjects [35,36], while
others show no effect [37,38]. Air pollution due to
increased ozone levels appears to increase FeNO levels
particularly in asthmatics, possibly due to increased iNOS
expression in airway epithelium in an AP-1- and STAT-1-
dependent mechanism [6].
Most external factors reported to influence FeNO have
only small and clinically nonsignificant effects. However,
three major confounders can be distinguished; cigarette
smoking, virus infections and certain food intake. These
confounders are summarized in Table 1 with suggestions on
how to deal with them in clinical practice.
It should also be noted that absolute FeNO values vary
depending on the device used. A study by Boot et al.
showed that a chemiluminescence device and an electro-
chemical device, from two different manufacturers, couldurements, their approximate effect size and advice on how to
Measure
nt on Use intraindividual changes, for example
after introduction of anti-inflammatory therapy
Repeat measurement after at least 14 days
peak Ask patients to refrain from a meal consisting
primarily of green-leaved vegetables on the
day of assessment, or at least record such intake
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iluminecence device produced slightly lower values [39]. To
maintain accuracy in interpretation and comparison of
FeNO values, it is essential that the same device is used
during research and in general clinical practice, as cali-
bration procedures may differ between devices [5].
Clinical applications of FeNO
Diagnosing and assessing ICS-responsive
inflammatory airway disease
Asthma is a chronic inflammatory airway disease associated
with airway hyperresponsiveness (AHR) [40,41]. While the
majority of asthma is associated with eosinophilic inflam-
mation, not all patients exhibit this feature [42]. Various
studies have shown that in individuals with asthma,
increased FeNO levels are associated with eosinophilia in
blood, sputum, bronchoalveolar lavage (BAL) fluid and
airway mucosa [3,13,43e45]. FeNO is potentially a valuable
aid in asthma diagnosis; in a study comparing FeNO and
sputum cell counts against serial peak flow recordings and
spirometry in children and adults, the sensitivity of
spirometry was lower (47%) than that of either FeNO (88%)
or sputum eosinophils (86%). FeNO and sputum eosinophils
additionally exhibited a specificity of 92% as compared with
73% for spirometry [46].
FeNO has long been regarded as a surrogate marker of
eosinophilic airway inflammation. Recent studies, however,
indicate that FeNO is more representative of a Th2-driven
local inflammation, specifically of the bronchial mucosa,
rather than general eosinophilic inflammation, as measured
by blood or induced sputum. For example, FeNO levels
correlate betterwith bronchial eosinophils thanwith sputum
eosinophils [6,47,48]. The disconnect between FeNO and
eosinophilic inflammation has been highlighted by studies
with monoclonal antibodies (mAb) against IL-5 and IL-13,
which show that treatment with mepolizumab, an anti-IL-5
mAb, significantly reduces blood and sputum eosinophils
without affecting FeNO levels [48], while treatment with
lebrikizumab, an anti-IL-13 mAb, significantly reduces FeNO
levels without reducing blood eosinophils [49].
Consequently, an important attribute of FeNO is its ability
to potentially predict the response to ICS therapy in asthma
and other inflammatory airway conditions [12,50e53].
Research suggests that subjects (especially patients with
asthma) with elevated baseline FeNO levels are more likely
to respond to ICS [12] and, in most cases, show a rapid
reduction in FeNO levels upon initiation of ICS treatment
[54]. In contrast, those with baseline FeNO levels in pre-
defined normal ranges are less likely to respond to ICS [12]. A
relatively small study by Smith et al. investigated the utility
of FeNO in predicting an ICS response in patients aged 12e75
years with persistent, previously undiagnosed respiratory
symptoms [12]. Regardless of the final diagnosis, patients in
the highest FeNO tertile (>47 ppb) had significantly greater
responses to inhaled fluticasone (increase in FEV1, increase
in mean morning peak flows, improved symptoms and
reduction in AHR to adenosine monophosphate [AMP]) than
those in themid (15e47 ppb) or low (<15 ppb) FeNO tertiles.
However, less than half of patients in the mid-tertile werelater diagnosedwith asthma, as comparedwith almost 90% in
the high tertile, which probably explains the low degree of
ICS responsiveness in the subjects with intermediate FeNO
levels [12]. Hahn et al. demonstrated that in subjects aged
18 years with uncontrolled chronic cough, those with
elevated FeNO levels (35 ppb) had a higher likelihood of
responding positively to ICS therapy than those with lower
FeNO levels (<35 ppb) [50]. In patients with COPD, some of
whomshowaneosinophilic rather than theusual neutrophilic
inflammatory pattern [55,56], pre-ICS FeNO levels have been
shown to correlate positively with short-term improvement
in FEV1 to oral and inhaled corticosteroids [52,57]. Conflict-
ing evidence was reported by others, e.g. Klaassen et al.
reported that symptoms, but not FeNO levels, predicted a
positive response to ICS therapy in children with recurrent
wheeze who were later diagnosed with asthma [58]. Notably
however, in this study, FeNO was measured using an offline
(tidal breathing) method, rather than the recommended
online measurement. Prieto et al. reported that while a
significant proportion of patients (aged 18e70 years) with
chronic cough responded well to ICS, at a baseline cut-off of
20 ppb, FeNO was not useful in predicting this response [59].Management of ICS-responsive inflammatory airway
disease
Inhaled corticosteroids are recommended for long-term
control of persistent asthma in both children and adults
due to their ability to target the underlying airway
inflammation and to reduce the risk of asthma exacerba-
tions [40,60,61]. The relationship between clinical out-
comes and ICS dose is variable in asthma, and some patients
may require high ICS doses to achieve acceptable levels of
disease control. However, higher ICS doses increase the risk
of adverse effects such as oral candidiasis, dysphonia,
hoarseness, cataracts, and growth retardation in children
[62]. Optimum ICS dosing is important to promote patient
safety, whilst maintaining adequate asthma control and
minimising exacerbations.
Traditionally, ICS dose titration is based on assessment
of patient exacerbation history, symptoms and standard
lung function tests. A number of studies have investigated
the value of FeNO in the management of asthmatic pa-
tients, particularly in predicting the risk of exacerbations,
in dose titration, and in assessing compliance to ICS. Dose
titration studies have been inconsistent, with some studies
reporting benefits and others not. Smith et al. randomly
allocated 97 asthmatic patients requiring ICS to treatment
adjustment based on FeNO measurements or conventional
guidelines. As compared with the control group, FeNO-
guided therapy resulted in a significant reduction in the
mean ICS dose in the active group (641 vs 370 mg;
p Z 0.003), accompanied by a non-significant trend to-
wards reduced exacerbation rates (0.49 vs 0.90) [63].
Powell et al. used a FeNO-based treatment algorithm to
optimise ICS dosing in non-smoking, pregnant asthmatic
women. Patients were randomly assigned to ICS adjustment
using either clinical symptoms (control group) or FeNO
levels (active group). ICS doses were increased at FeNO
concentrations >29 ppb and reduced at <16 ppb. The mean
maintenance daily ICS dose and exacerbation rates were
834 L. Bjermer et al.significantly lower in the FeNO-guided group than in the
control group (ICS dose: p Z 0.043; exacerbation rates
0.288 vs 0.616, p Z 0.001) [64]. More recently, a multi-
centre study performed within primary healthcare by Syk
et al. showed improved asthma outcomes without an in-
crease in overall ICS use [65]. Asthmatics were randomised
to treatment with ICS and a leukotriene receptor antagonist
guided either by FeNO values (active group) or to standard
care (control group) and followed for 1 year. In the active
group, treatment was stepped up at a FeNO level of
25 ppb and stepped down at <20 ppb. The FeNO-guided
group showed significantly improved asthma control (Juni-
per ACQ score) compared with the control group, and the
exacerbation rate was reduced by almost 50%. However,
some other studies have failed to significantly show that
FeNO-guided treatment strategies provided further bene-
fits in asthma control, when compared with conventional
strategies [66e68]. Szefler et al. conducted a randomised,
double-blind, parallel-group trial in 546 inner-city adoles-
cents and young adults (aged 12e20 years) with persistent
asthma and demonstrated that the addition of FeNO mea-
surements to guideline-based clinical care resulted in
significantly higher ICS-doses (118.9 mg/day difference,
p Z 0.001) without clinically important improvements in
asthma control. However, FeNO-guided care produced a
significant reduction in the risk of requiring at least one
prednisone course for asthma exacerbations [67]. Further-
more, post-hoc analyses highlighted that subgroups of
asthmatics with obesity, higher blood eosinophil count and
greater atopy may benefit from FeNO measurement [67].
de Jongste et al. investigated the effect of daily tele-
monitoring of asthma symptoms plus-minus FeNO mea-
surements on the management of 151 atopic asthmatic
children [66]. Both approaches were associated with
improved asthma control and lower ICS use with no statis-
tical difference between study groups. ICS doses were only
adjusted every 3 weeks and the authors acknowledge more
frequent FeNO-based dose adjustments may have produced
better outcomes. In a randomised, single-blind trial by
Shaw et al., based either on FeNO measurements or the
British Thoracic Society (BTS) guidelines in 118 asthmatic
participants [68], a non-significant reduction in asthma
exacerbations was achieved together with a significant
reduction in final ICS dose in the FeNO-guided group
compared with the guidelines-based group. More recently,
a study by Calhoun et al. was not able to show a reduced
incidence of treatment failure, which was the primary
endpoint, by a FeNO-based strategy compared to either a
physician-based or a symptom-based strategy [69]. How-
ever, the study included primarily patients with mild, well-
controlled asthma, which means that very little room was
left for further improvement with regard to treatment
failures. In a subanalysis by season, the authors showed a
significantly lower incidence of treatment failures during
the autumn, which is a high-risk season, by the FeNO-based
strategy compared to the physician-based strategy.
Furthermore, the FeNO strategy provided a significant
improvement in daily symptoms as well as methacholine
reactivity compared to the physician-guided group.
It is clear that methodological issues and cut-off points
used in the different FeNO-guided intervention studies may
explain discrepancies between studies. Consequently, aCochrane review, comparing ICS-adjustments based on
either FeNO measurements or clinical symptoms,
concluded that FeNO could not be routinely recommended
for clinical practice at this time and that further studies
were warranted [70]. The primary outcome in this meta-
analysis was the proportion of subjects with at least one
asthma exacerbation, so the analysis did not account for
subjects with multiple exacerbations [4,71]. Further
possible analyses include annual exacerbation rates or time
to first exacerbation, which has been recommended by an
ATS/ERS Task Force on outcomes in asthma clinical trials
[72]. Two more recent meta-analyses based on exacerba-
tion rates, have reported that FeNO-guided asthma man-
agement was superior to conventional methods [4,71].FeNO measurement in paediatrics
FeNO may be of particular interest for diagnosing and
phenotyping asthma in children with suspected asthma,
aiming to achieve optimal treatment and asthma control.
Diagnosing asthma in children, particularly preschoolers,
may be challenging. Moeller et al. reported that in
wheezing children aged 3e47 months, FeNO levels were
significantly higher in children with frequent recurring
wheeze and a stringent index for the prediction of asthma
as compared to children with early recurrent wheeze and a
loose index for the prediction of asthma, or children with
recurrent cough but no wheeze; thus predicting disease
progression [73]. This information may help clinicians
identify which children are potential ICS responders [74].
Although monitoring of asthma control in primary care is
currently mainly focused on the evaluation of clinical
symptoms and lung function parameters, GINA guidelines
and ATS FeNO guidelines suggest that airway inflammation
could be assessed for optimised treatment strategies
[41,75]. However, in patients of all ages, a dissociation be-
tween control evaluation tools, such as validated question-
naires, and the level of underlying airway inflammation has
been demonstrated [76]. While a reduction in FeNO levels
can be indicative of a response to ICS treatment [77], high
FeNO levels are indicative of a higher probability of asthma
relapse on ICS reduction or withdrawal [77e79]. Based on
these data, other studies have investigated the effects of
FeNO-guided corticosteroid titration in children with partly
conflicting outcomes [66,67,80,81]. Possible explanations
for inconsistency in findings have been proposed in the
Asthma randomised Treatment Algorithm (ASTRAL) studies
report, highlighting design and methodological issues, which
may have led to different conclusions between studies as
discussed above [82]. In a recent single-blind, randomised,
controlled study in 99 paediatric patients with persistent
allergic asthma a FeNO-guided measurement strategy failed
to improve the proportion of symptom-free days, but was
associatedwith fewerasthmaexacerbations, increasedLTRA
use and augmented ICS doses [83].
Currently, FeNO may be considered as a potentially
useful adjunctive tool in clinical paediatric practice, in
particular in specialist settings, in order to better charac-
terise airways inflammation in children with wheezing, as a
guide to ICS use and to achieve a more comprehensive
assessment of disease control.
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Exhaled nitric oxide may have a role in assessing adherence
to ICS therapy, since FeNO responds rapidly and dose-
dependently to ICS treatment [84]. This is beneficial
because adherence with ICS therapy is a critical prerequi-
site for asthma control. Beck-Ripp et al. evaluated
compliance with inhaled budesonide in children by moni-
toring FeNO levels following sequential changes in treat-
ment. As opposed to standard lung function tests, there
was a significant correlation between FeNO and compliance
[85]. Koster et al. reported that increased FeNO levels
(>25 ppb) in children prescribed ICS were associated with a
reduced adherence (OR Z 0.25, 95%CI Z 0.15e0.41). The
authors suggested that improving parental knowledge of
drug characteristics and feedback of FeNO readings could
positively influence adherence and thus improve asthma
control [86]. Finally, McNicholl et al. showed that when
patients with difficult-to-treat asthma treated with bude-
sonide were monitored based on changes in FeNO levels,
adherent subjects had a greater reduction in FeNO [87].
Guiding treatment response to drugs other than ICS
In asthma, corticosteroids primarily act on the Th2-mediated
cytokine release and subsequent inflammatory response. As
ICSs are the standard therapy for patients with allergic
airway inflammation, most research has focused on the use
of FeNO in tailoring ICS treatment. However, data on its value
in determining a response to other treatments including
leukotriene-receptor antagonists (LTRAs), and biological
drugs including omalizumab (anti-IgE), lebrikizumab (anti-
IL-13) andmepolizumab (anti-IL-5), which specifically target
the Th2-pathway, are emerging. For example, studies have
shown that FeNO can be useful in predicting a response to
LTRAs in patients with asthma [88,89]. Omalizumab is indi-
cated for the treatment of patients with inadequately
controlled severepersistent allergic asthmadespitemaximal
controller therapy. Hanania et al. evaluated the value of
FeNO in predicting exacerbation rates in such patients and
showed that those in the high FeNO subgroup had greater
reductions in exacerbations by omalizumab treatment as
compared with those in the low FeNO subgroup (53% vs 16%)
[90]. While the authors suggest that additional studies are
required to explore the value of FeNO, this study strongly
suggests its value as a predictor of responsiveness to omali-
zumab treatment [90]. Corren et al. investigated leb-
rikizumab treatment in patients with uncontrolled asthma.
Greater lung function improvements, measured by % change
in FEV1 at 12 weeks, were observed in patients with high
pretreatment serum periostin (an IL-13-induced epithelial
protein) and FeNO levels (14.0% and 14.2%, respectively)
than in those with low periostin and FeNO levels (5.1% and
4.8%, respectively) [49].
Predicting future risk: exacerbations and lung
function decline
In children and adults with atopic asthma, Zeiger et al.
showed that a FeNO level >300% of expected normal
(approximately 35e50 ppb depending on individual factors)predicted both impairment (excessive use of short-acting
bronchodilators) and risk (exacerbations with prednisolone
courses) in the following year [91]. In an adult population,
combined use of FeNO and FEV1, predicted the risk of an
exacerbation. In this study conducted over 18 months, at
FeNO levels of 28 ppb and FEV1 76%, clinically stable
asthmatics were shown to have an 85% probability of a
future exacerbation, while at FeNO levels of 28 ppb and
FEV1 >76%, there was no risk of exacerbation [92]. FeNO
has also been shown to be useful in predicting loss of
asthma control following corticosteroid withdrawal. Jones
et al. [93] withdrew ICS therapy from 78 adult patients aged
18e74 years with mild-moderate asthma for a maximum of
6 weeks or until they lost asthma control. In those patients
who lost asthma control (77.9%), there was a significantly
greater increase in baseline FeNO levels, as compared with
patients who maintained control (2.16-fold vs 1.44-fold,
respectively; pZ 0.004). FeNO was additionally associated
with a positive predictive value of 80%e90% for predicting
and diagnosing loss of control [93]. In another study in
children, at a cut-off value of 49 ppb, FeNO exhibited a
sensitivity of 71% and a specificity of 93% for predicting
asthma relapse (defined as more than one exacerbation per
month, or need for beta-agonist treatment 4 days per week
for at least 2 weeks, or diurnal peak flow variability of >20%
after discontinuation of corticosteroids) [78].
FeNO may also predict future lung function decline. [4]
Sonnappa et al. investigated the correlation between
airway pathology at age 2 and lung function at age 5 (me-
dian) in previous severe preschool wheezers by performing
biopsies, lung function tests and FeNO measurements.
Reticular basement membrane (RBM) thickness and
mucosal eosinophilia (but not lung function) measured at
age 2 significantly correlated with FeNO measurements at
age 5 [94]. Multiple-trigger wheeze in children is associated
with abnormal pulmonary function, whereas episodic (viral)
wheeze is not [95]. Sonnappa et al. previously demon-
strated that despite similar lung function in both groups,
multiple-trigger wheezers exhibit significantly higher FeNO
levels than episodic wheezers [95]. Van Veen et al. re-
ported that FeNO could predict an accelerated decline in
lung function in asthma patients refractory to ICS therapy.
FeNO levels of 20 ppb (measured at an exhalation flow
rate of 100 mL/s) were shown to be associated with an
increased decline in FEV1 compared with FeNO levels of
<20 ppb, with an excess decline in lung function of
40.3 mL/year. Patients with a FeNO level of 20 ppb had a
57% risk of an accelerated decline in FEV1 (25 mL/year)
compared with 30% in patients with a FeNO level of <20 ppb
[96].
Proposed framework to guide FeNO use in
clinical practice
Clinical scope
The cornerstone of asthma diagnosis is the evaluation of
airway dysfunction and airway inflammation, while the aim
of asthma management is to achieve control, which ac-
cording to GINA/BTS guidelines constitutes prevention of
symptoms, night-time symptoms/awakening, the need for
836 L. Bjermer et al.rescue medication, exacerbations, limitations of activity
and the achievement of normal lung function (FEV1 and/or
PEF >80%) [40,41].
Current evidence suggests that FeNO is useful in: (i)
detecting Th2-driven inflammation of the lower airways in
conditions like asthma, chronic cough, eosinophilic bron-
chitis, and sometimes COPD; (ii) predicting a response to
ICS and other anti-inflammatory therapy; (iii) continued
disease monitoring and follow-up of asthma patients after
initial diagnosis using standard procedures. Taking into
consideration the previously discussed factors that influ-
ence FeNO values (i.e. age, height, gender, smoking,
allergen exposure, rhinovirus infections and nitrate intake)
we propose a framework to guide treatment decisions that
incorporates FeNO measurements into existing GINA/BTS
asthma management guidelines. However, further clinical
trials, preferably real-world studies, will be required to
investigate and validate each of these propositions.
Cut-off values for FeNO
Generic cut-off values are difficult to define due to the
effect of the aforementioned individual factors. The 2011
ATS FeNO guidelines suggest that a FeNO level of <25 ppb
(<20 ppb in children) provides a strong indication for an
unlikely ICS response, while a FeNO level of >50 ppb
(>35 ppb in children) provides a strong indication for a
likely ICS response. A FeNO level of between 25 and 50 ppb
(20e35 ppb in children) should, however, be interpreted
cautiously, and with reference to the clinical context, ac-
counting for persistent and/or high allergen exposure as aTable 2 Summary of the suggested clinical decision-making rol
suspected or diagnosed asthma.
FeNO levels and inflammation
FeNO (ppb) Normal Elevated
Adults <20e25a 20/25e50
Children <15e20a 15/20e35
Th2-driven inflammation Unlikely Likely
Initial assessment in treatment-naı¨ve patients with suspected
Guide to diagnosis Consider other diagnosis
than asthma
Supports a
Guide to treatment
decision
The patient will likely not
respond to ICS
The patie
to ICS. A
is suggest
Assessment in treated patients with a confirmed diagnosis of a
Guide to management Th2-driven inflammation is
under control
Check tre
inhalation
allergen e
Guide to treatment
change decision
Consider step-down of ICS
treatment
if the asthma has been
controlled for at least
3e6 months
If there is
exacerbat
anti-inflam
a Exact cut-off dependent on age, height and gender.factor associated with higher FeNO levels, according to
these guidelines [75]. However, more recent evidence from
a study on 154 steroid-naive adult patients with asthma
suggests that subjects with intermediate FeNO levels
(25e50 ppb, as defined above) respond to ICS treatment in
a similar fashion to patients with high FeNO levels
(>50 ppb), whereas patients with a low baseline FeNO
value (<25 ppb) respond much less [97]. This is in line with
the positive outcomes in the studies by Powell et al. and
Syk et al., where ICS treatment was stepped up at FeNO
levels of 29 and 25 ppb, respectively, in the FeNO-guided
groups [64,65]. Furthermore, Hanania et al. reported that
patients with a baseline FeNO level of approximately
20 ppb and above responded significantly more to omali-
zumab compared to patients below this level [90], and
Corren et al. reported that patients with a FeNO level
above 21 ppb responded better than patients with lower
values [49]. All the outcomes above are supported by the
study by Sverrild et al., which showed that a FeNO level of
<20 ppb ruled out mannitol reactivity with a sensitivity of
100% and a level of 30 ppb ruled in mannitol reactivity
with a specificity of 90% in an unselected sample of 180
steroid-naive, non-smoking adolescents and young adults
[19]. Moreover, our clinical experience suggests that many
patients with intermediate FeNO values, as defined by the
ATS guidelines may indeed respond positively to ICS.
Based on current evidence, it could be proposed that
treatment decisions are made using two cut-off levels: A
low cut-off range of 15e25 ppb, and a high cut-off range
of 35e50 ppb, with both cut-offs depending on individual
factors, for example age (see Table 2). These cutoffs aree of FeNO measurement in the management of patients with
High
>50
>35
Significant
asthma
diagnosis of asthma Supports a diagnosis of asthma
nt will likely respond
trial of low dose ICS
ed
The patient will likely respond
to ICS. A trial of intermediate
dose ICS is suggested
sthma
atment adherence,
technique and
xposure
Check treatment adherence,
inhalation technique and allergen
exposure. Indicates increased risk
of exacerbations/disease worsening
regardless of clinical history
a history of
ions, step-up
matory treatment
Step-up anti-inflammatory treatment,
especially if combined with high
blood eosinophil count, or consider
fine-particle ICS. May suggest
ICS-resistant asthma and need for
add-on systemic anti-inflammatory
therapy
FeNO measurement in respiratory diseases 837suggested to be used differently depending on the clinical
situation (see below).
Clinical algorithms guided by FeNO
To aid initial diagnosis/treatment decisions in previously
untreated patients with uncertain diagnosis (see also Table
2):
 A FeNO value below the low cut-off (15e25 ppb) could
be interpreted as a low likelihood of Th2-driven inflam-
mation and an unlikely response to ICS/anti-
inflammatory therapy in a (non-smoking) treatment-
naive patient. A FeNO value below this cut-off in a
previously undiagnosed patient probably indicates non-
Th2-driven inflammation and a diagnosis other than
asthma or eosinophilic bronchitis. The diagnosis should
be re-evaluated and other (anti-inflammatory) treat-
ment strategies should be investigated.
To guide treatment decisions in diagnosed patients with
ongoing anti-inflammatory treatment:
 A FeNO value above the high cut-off (35e50 ppb) could
be interpreted as a high degree of Th2-driven inflam-
mation and a high likelihood of asthma diagnosis, with
increased risk of worsening of symptoms and exacerba-
tions in asthmatics with ongoing treatment, especially
when combined with elevated blood eosinophil count
[18]. A level above this cut-off indicates a check-up of
treatment adherence including inhalation technique and
environmental exposures plus-minus the need for step-
ping up or change to other anti-inflammatory treatment.
To manage/monitor treatment decisions, the change in
FeNO following anti-inflammatory therapy may be more
applicable and easier to interpret than an absolute FeNO
value:
 A reduction in FeNO from a higher range to a lower range
(see Table 2) could be interpreted as a high likelihood of
a positive response to the introduction or the step-up of
ICS or other anti-inflammatory therapy.
Future directions and conclusions
As highlighted within this publication, there are still several
areas that need further investigation to strengthen the
clinical and cost benefits of FeNO measurement in the
standard diagnosis and management of respiratory
diseases.
Some pertinent questions to demonstrate the clinical
and cost benefits of FeNO measurements in this area might
include:
 Does a low FeNO value preclude the long-term need for
ICS treatment in an untreated patient?
 Does FeNO measurement provide better asthma control?
 Why do some studies fail to show a clinical benefit for
adjunctive FeNO measurements?
 Which patient groups do most likely benefit from FeNO-
based ICS-titration? Is there a role for alveolar nitric oxide measurements in
standard clinical practice and if so, for which patients?
 What is the clinical and economical yield of FeNO mea-
surements in real-life settings as a tool to facilitate the
diagnosis and treatment of inflammatory airway
diseases?
Thus far, evidence regarding the value of FeNO mea-
surement for the diagnosis and management of inflamma-
tory airway diseases has not been unequivocally supportive
due to a number of perturbing factors: differences in study
designs, sample size, methodology, clinical parameters,
the application of different FeNO algorithms and devices,
and inconsistencies in predefined study endpoints. Despite
these factors, when used to assess ICS-responsive disease in
conjunction with clinical data and standard lung function
tests, current evidence supports the additional value of
FeNO measurements. FeNO is capable of providing
discriminating information on Th2-driven airway inflam-
mation, in a simple, fast, non-invasive and reproducible
manner. FeNO measurement is even simpler than spirom-
etry and may thus easily be implemented even within pri-
mary care. To date, no other test possesses these
attributes. As such, FeNO has been shown to provide
additional useful information for clinical practice to aid
diagnosis, predict and tailor responsiveness to ICS and
biological therapies, and to assess therapy compliance. In
this manner, FeNO may be a useful asset to cost-effective,
personalised medicine. FeNO use has been associated with
lower exacerbation rates and can assist in the identifica-
tion of patients with distinct asthma phenotypes, e.g.
those at risk of future lung function decline or loss of
asthma control during ICS or biological therapy. While
ongoing research will provide further evidence that should
quell lingering doubts, current evidence suggests that the
routine use of FeNO in conjunction with conventional
clinical measures and lung function tests could help the
diagnosis and management of inflammatory airway disease,
particularly asthma.
Approaches directed at improving asthma diagnosis and
management could lower healthcare costs as well as
improve quality of life in patients with poorly controlled
asthma and those unnecessarily prescribed ICS [98]. Some
health economic models in Europe suggest the use of FeNO
in the management of persistent asthma and potentially in
the diagnosis of asthma provides cost savings [98,99].
However, further health economic evaluations and real-
world observational studies are required to validate the
cost-effectiveness of FeNO measurements in asthma diag-
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